Not yet recruiting

Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma

By April 24, 2017 No Comments

Condition

Malignant Pleural Mesothelioma

Estimated Enrollment: 24

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 2015-0856|NCI-2016-01923

Study First Received: November 7, 2016

Last Updated: April 19, 2017

Estimated Primary Completion Date: June 2020

 

Primary Outcome Measures:

Treatment-Related Toxicity of Adding Pembrolizumab with Radiation Therapy in Participants who Have Undergone at Least 2 Cycles of Chemotherapy and Possible Lung-Sparing Surgery|Treatment-Related Toxicity of Adding Pembrolizumab with Radiation Therapy in Participants who Have Possibly Received Prior Chemotherapy and No Surgery|Tumor Response

Sponsors and Collaborators:

M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.

Website Link: https://ClinicalTrials.gov/show/NCT02959463

Leave a Reply

Call Now